SKP2 and Familial prostate cancer: Treatment with MLN4924 has been shown to decrease Skp2 protein levels in prostate cancer cell lines PC3, PC3, DR12, and LAPC4 as well as decreasing Slug expression, indicating that neddylation blockade is a potential therapeutic approach for advanced prostate cancer (Mickova et al., 2021).